Aptevo to present CD40-directed multispecific platform at SITC 2026, Nov 4-8 in Phoenix

Aptevo Therapeutics Inc.

Abstract 1060, "Leveraging multispecific antibody-like molecules to localize CD40 agonism to the tumor," to be presented by Michelle Nelson, PhD, at SITC 2026 in Phoenix.
Presentation covers Aptevo's broader CD40-directed multispecific portfolio, designed to combine innate and adaptive immune activation within the tumor microenvironment.
Company says tumor-directed CD40-activating molecules localize immune activation at the tumor while seeking to limit systemic immune activation.
CSO Mary Janatpour, PhD, cited the work as continued evolution of the multispecific platform targeting persistent solid-tumor challenges.
Slides to be posted on Aptevo's website Publications page after the November 4-8, 2026 meeting; no clinical data or timelines disclosed.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.